Kura Oncology to Participate in Two Investor Conferences in November
Kura Oncology, Inc. Q3 2026 Earnings Call Summary
Kura Oncology Inc (KURA) (Q3 2026) Earnings Call Highlights: KOMZIFTI Revenue Surges 53% as ...
Kura Oncology (KURA) Q3 2026 Earnings Call Transcript
Kura Oncology Q3 Earnings Call Highlights
Kura Oncology, Inc. (KURA) Q3 2026 Earnings Call Transcript
Kura Oncology: Q3 Earnings Snapshot
Kura Oncology (KURA) Reports Q3 Loss, Beats Revenue Estimates
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
Kura Oncology Files Shelf Prospectus For Offering; Size Not Disclosed
Kura Oncology (KURA) Loses 35.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
Reported Earlier: Kura Oncology And Kyowa Kirin To Present Eight Ziftomenib Abstracts At ASH 2026, Highlighting Promising AML Combination Data And Expanded Clinical Potential
Kura Oncology to Report Third Quarter Financial Results on November 10
Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor
Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes - Slideshow
Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.